.After antibody-drug conjugate (ADC) expert Seagen was marketed to Pfizer in 2015 for an immense $43...
.On the heels of a period 3 win that fell short to impress clients, Ironwood Pharmaceuticals is back...
.Don't stop Monte Rosa Therapies now. The Boston-based biotech is actually having a ball after signi...
.Accept to this week's Chutes & Ladders, our roundup of substantial leadership hirings, shootings...
.Celebrating his firm's upsized initial public offering (IPO), Septerna chief executive officer Jeff...
.AbbVie has gone back to the source of its own antipsychotic goliath Vraylar searching for an additi...
.GenSight Biologics is actually weeks far from losing amount of money. Once again. The biotech only ...
.Monopar Rehabs is actually bouncing back a medication from the scrap heap of AstraZeneca's unusual ...
.With new records out on Arcus Biosciences' experimental HIF-2a prevention, one group of experts fig...
.After developing a genetics treatment partnership with Dyno Therapeutics in 2020, Roche is back for...
.Lundbeck is lowering the book value of its $250 million Abide Rehabs buyout in reaction to stage 1 ...
.The combination of real-world records (RWD) right into procedure feasibility and also website varie...
.At this year's Ferocious Biotech Top in Boston ma, our team overtook innovators in the biotech sect...
.Merck & Co. is putting down $30 thousand ahead of time to purchase Yale spinout Modifi Bioscienc...
.Alpha-9 Oncology has increased a $175 thousand set C round to money its own clinical-stage radiopha...
.Eye drug manufacturer Ocuphire Pharma is actually getting genetics treatment developer Piece Genes ...
.Roche's chronic coughing program has faltered to a standstill. The drugmaker, which axed the course...
.Gilead Sciences as well as Merck & Co. have assisted their once-weekly HIV mixture treatment pas...
.Lykos Therapies may possess shed three-quarters of its own team in the wake of the FDA's rejection ...
.Septerna may be as yet to disclose "any sort of relevant professional information," but the biotech...